Monitor for partnership announcements and EVX-01 three-year data in H2 2026. Current cash runway into H2 2027 suggests no near-term financing urgency, but the widened net loss and pre-revenue status imply eventual capital needs.
Price Chart
Executive Summary
Evaxion reported Q1 2026 results with net loss widening to $3.6M from $1.6M due to lower financial income, while operating expenses remained roughly flat. Cash of $18.4M provides runway into H2 2027. R&D progress includes positive immunogenicity data for EVX-01 (86% target recognition) and completion of phase 2 extension, but no new partnerships or near-term catalysts were announced.
Key Facts
- Net loss Q1 2026: $3.6M vs $1.6M Q1 2025 (increase due to lower financial income)
- Operating loss slightly improved: -$3.819M vs -$3.868M
- Cash and equivalents: $18.4M as of March 31, 2026 (down from $23.2M at Dec 31, 2025)
- Cash runway confirmed into second half of 2027
- No revenue; zero revenue in both periods
- 86% vaccine target recognition rate reported for EVX-01 from AACR data
- Phase 2 extension for EVX-01 completed; three-year data expected H2 2026
- New polio vaccine design concepts presented from Gates Foundation collaboration
- Promoted Chief Scientific/COO and added new Board member with dealmaking experience
Financial Impact
Net loss increased $2.0M YoY due to $2.2M decline in financial income; cash burn ~$3.6M/quarter
Risk Factors
- No near-term revenue and increasing net loss
- Need for additional capital beyond current runway
- Clinical trial risks for EVX-01 and pipeline candidates
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-003114 |
| Document: f6k_050726.htm | 0001171843-26-003114 |
| Document: 0001171843-26-003114-index-headers.html | 0001171843-26-003114 |
| Document: 0001171843-26-003114-index.html | 0001171843-26-003114 |
| Document: 0001171843-26-003114.txt | 0001171843-26-003114 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $3.07 $3.21 | ▲ +4.56% | ▲ +4.45% | $3.21 (+4.63%) |
Sep 4, 2026 28d ago | 6-K | $3.12 $3.07 | ▲ +1.60% | ▲ +0.39% | $3.21 (−2.96%) |
Aug 20, 2026 6w ago | 6-K | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.07%) |
Aug 20, 2026 6w ago | Press Release | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.07%) |
Aug 17, 2026 6w ago | 6-K | $3.13 $3.40 | ▲ +8.63% | ▲ +9.82% | $3.21 (+2.63%) |
Aug 14, 2026 7w ago | 6-K | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.83%) |
Aug 14, 2026 7w ago | Press Release | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.83%) |
Jul 17, 2026 11w ago | 6-K | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.46%) |
Jul 17, 2026 11w ago | Press Release | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.46%) |
Jul 13, 2026 11w ago | 6-K | $3.02 $3.08 | ▲ +1.82% | ▲ +2.61% | $3.21 (+6.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access